Headaches on a GLP-1 Microdose: Why They Happen, How Long They Last, and What the Trials Show

Nausea gets the headlines, but headache is one of the side effects people notice most in the first weeks of a GLP-1. In STEP 1, 15.2 percent of people on semaglutide 2.4 mg reported one. So did 10.4 percent of people on placebo.

That gap of about five percentage points is the part the drug is responsible for, and it is smaller than most people assume. The bigger story is what a GLP-1 does to daily routine. People eat less, drink less, skip the second coffee, and go longer between meals. Each of those is a well known headache trigger in its own right, and they tend to arrive together in the first month of treatment and again after each dose increase.

This article covers how often headaches occur in the trials, why they happen, when they tend to appear and fade, how caffeine and fluid intake fit in, what the early research on migraine and raised brain pressure shows, and which headaches are not the typical GLP-1 kind.

How common are headaches on semaglutide and tirzepatide?

Common, but only partly caused by the drug

Headache is one of the more frequent non gastrointestinal side effects of GLP-1 medicines, and the placebo arm shows how much of it would happen anyway. In STEP 1, which followed 1,961 adults for 68 weeks, headache was reported by 15.2 percent of the semaglutide group and 10.4 percent of the placebo group. Headaches are common in daily life, so any long trial collects a lot of them regardless of treatment. The excess of roughly 5 percentage points is the fairer estimate of what semaglutide adds.

Headache appears in the prescribing information for semaglutide, liraglutide, and tirzepatide, usually described as mild to moderate and short lived. Very few trial participants stopped treatment because of headache alone. Nausea was far more likely to lead to discontinuation.

The pattern in the chart below is useful to keep in mind. The four gastrointestinal effects all show a gap of two to four times over placebo. Headache shows a much smaller relative gap, which fits the idea that it is mostly a downstream effect of eating and drinking less rather than something the drug does to the head directly.

Why do GLP-1 medications cause headaches?

Less food, less water, less salt, less caffeine

GLP-1 headaches mostly come from the changes the drug makes to eating and drinking, not from a direct action on the brain. Four mechanisms account for most of them, and they often stack.

Lower fluid intake. Food supplies roughly 20 to 30 percent of the water an adult takes in each day, more with soups, fruit, and vegetables. Someone who eats 30 percent less on a GLP-1 loses a slice of that water without noticing. GLP-1 drugs also appear to reduce thirst and drinking in both animal and human studies, and feeling full makes a large glass of water less appealing. The hydration article on this site goes through the numbers in detail.

Less salt and longer gaps between meals. Smaller meals carry less sodium, which lowers blood volume a little and can bring on light headedness and a dull headache, especially on standing. Going six or seven hours without food is also a recognised headache trigger. A study of people fasting on Yom Kippur found that roughly 4 in 10 developed a headache during the 25 hour fast.

Nausea and vomiting. Nausea reduces drinking further, and vomiting removes fluid and salt directly. Anyone with ongoing vomiting on a GLP-1 is at real risk of dehydration, which in turn is a risk to kidney function. That situation needs a call to the prescriber rather than a pain reliever.

Can a GLP-1 cause caffeine withdrawal headaches?

The coffee you stopped wanting still counts

Yes, and caffeine withdrawal is one of the most overlooked causes of headache in the first weeks on a GLP-1. People often drop from three coffees to one because they feel full, because coffee worsens nausea, or because they have stopped eating the breakfast they used to have it with. The body does not register this as a healthy change. It registers withdrawal.

Juliano and Griffiths reviewed 57 experimental and 9 survey studies of caffeine withdrawal in 2004. They found headache in about half of regular users who stopped, with symptoms starting 12 to 24 hours after the last dose, peaking between 20 and 51 hours, and lasting 2 to 9 days. Withdrawal occurred even in people used to as little as 100 mg a day, about one small mug of brewed coffee.

The fix is to keep caffeine steady, or to reduce it on purpose by about a quarter every few days if cutting back is the goal. The caffeine article on this site explains how coffee interacts with GLP-1 appetite and gastric emptying effects.

How long do GLP-1 headaches last?

Usually two to four weeks after each change

GLP-1 headaches usually cluster in the first two to four weeks after starting the medication or raising the dose, then ease as eating, drinking, and caffeine habits settle. The trials report the same shape for nausea: the highest rates appear during dose escalation and fall away during the maintenance phase. Headaches linked to lower intake follow the intake, so they tend to fade once a person learns to eat and drink on a schedule rather than waiting for hunger or thirst.

Some people notice a headache on the day after the weekly injection, when drug levels and appetite suppression are highest. The missed dose article on this site describes how semaglutide levels rise and fall across the week. On a microdose protocol with smaller, more frequent doses, that peak is flatter, which is one reason some people find a daily or twice weekly schedule easier to tolerate.

A headache that is present most days for more than a month, that wakes a person from sleep, or that is getting steadily worse does not fit the usual pattern. It deserves a proper assessment rather than being put down to the medication.

Do GLP-1 drugs make migraine better or worse?

Early research points toward lower brain pressure

For people with migraine, a GLP-1 can work in both directions, and the early research on the direct brain effects is more encouraging than the side effect tables suggest. Skipped meals and dehydration are established migraine triggers, so a person with migraine may notice more attacks in the first weeks. That is the indirect effect described above.

The direct effect looks different. Botfield and colleagues showed in 2017 that exendin-4, the GLP-1 agonist behind exenatide, reduced cerebrospinal fluid secretion and intracranial pressure in rats. The IIH:Pressure trial, published by Mitchell and colleagues in Brain in 2023, then tested exenatide in 15 women with idiopathic intracranial hypertension, a condition of raised brain pressure that causes severe daily headache. Exenatide lowered intracranial pressure within hours and at 12 weeks, and monthly headache days fell by roughly 7 to 8 days.

Some researchers think subtle rises in intracranial pressure contribute to chronic migraine in people with obesity. Braca and colleagues in Naples tested that idea with liraglutide in a small open label pilot of adults with obesity and chronic migraine, published in Headache in 2025. Mean monthly headache days fell from about 20 to about 11 over 12 weeks, and the improvement did not track weight loss closely. There was no placebo group, and migraine studies are known for large placebo responses, so the result is a reason for proper trials rather than a finding in its own right.

What helps a headache on a GLP-1?

Five checks before anything else

Most early GLP-1 headaches respond to fixing the intake changes behind them. The checks below are general context to discuss with a prescriber or pharmacist, not individual advice.

Which headaches on a GLP-1 are warning signs?

Not every headache is the medication

A sudden, severe headache that reaches full strength within about a minute needs emergency assessment, whatever medication a person is on. The same applies to a headache with fever and a stiff neck, new weakness or numbness, confusion, trouble speaking, or a change in vision. None of these fit the mild, dull, early pattern of a GLP-1 headache.

Two GLP-1 specific situations also need prompt attention. Severe upper abdominal pain that spreads to the back, with repeated vomiting, can signal pancreatitis, and the headache that comes with it is a symptom of dehydration rather than the main problem. The pancreatitis article on this site covers the warning signs. Sudden painless loss of vision in one eye needs same day assessment because of the reported association between semaglutide and NAION, discussed in the eye health article.

For people with diabetes who also take insulin or a sulfonylurea, a headache with shakiness, sweating, or confusion may be low blood sugar. The hypoglycemia article on this site explains why this is rare on a GLP-1 alone but more likely in combination.

What is still unknown about GLP-1 headaches?

Gaps worth naming

No trial has reported headache rates on a deliberate low dose or microdosing protocol. The expectation that smaller doses cause fewer headaches rests on the broader finding that GLP-1 side effects rise with dose and with faster escalation, and on the indirect mechanism: less nausea and a smaller drop in intake should mean less dehydration. That reasoning is sound, but it has not been measured.

The migraine question is also open. The intracranial pressure findings are consistent across rat studies and a small human trial, and several larger migraine trials of GLP-1 drugs have been registered. Until those report, nobody can say whether a GLP-1 reduces migraine in people without raised brain pressure, or at what dose.

Frequently Asked Questions